Evaluation of EP102 for Safety and Efficacy in Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the **safety** and **efficacy** of EP102 in patients with advanced solid tumors. This is clinically relevant as it aims to determine the potential therapeutic benefits and risks associated with EP102, which could inform treatment strategies for individuals with these malignancies. No secondary objectives are provided.

The clinical trial involves **participants with advanced solid tumors**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the **safety** and efficacy of EP102 in patients with advanced solid tumors. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research aimed at assessing the safety profile of a new investigational drug. The trial will employ a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is July 1, 2025, with the trial expected to conclude by January 18, 2029, indicating a total duration of approximately three and a half years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment to ensure that participants meet the necessary conditions for trial inclusion. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are crucial for monitoring the participants' health status, assessing the drug's safety, and evaluating its efficacy. The end-of-study visit will mark the conclusion of a participant's involvement, during which final assessments will be conducted to gather comprehensive data on the investigational drug's impact.

The expected length of participant involvement will vary depending on individual response and the specific protocol requirements, but it is anticipated to span several months. Conditions that may lead to early termination from the study include adverse reactions to the investigational drug, withdrawal of consent, or any significant protocol deviations. The trial is designed to ensure participant safety and the integrity of the collected data, adhering to ethical standards and regulatory requirements throughout its duration.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial assessment of the investigational product's safety and potential efficacy. The trial is scheduled to commence recruitment on July 1, 2025, with an estimated completion date of January 18, 2029. Although specific efficacy endpoints are not detailed, Phase 1 trials typically focus on safety and pharmacokinetics, with preliminary efficacy data often collected as secondary outcomes. The trial will likely employ standardized methods for data collection and analysis, consistent with Phase 1 objectives, to ensure reliable and valid results. The absence of detailed endpoints suggests that the trial may utilize exploratory measures to identify potential efficacy signals, which will inform subsequent trial phases.